OR WAIT null SECS
INC Research, LLC announced the acquisition of Trident Clinical Research to expand its clinical trials outsourcing footprint and expertise in Australia, New Zealand, and India. Under the terms of the agreement, Trident will become a wholly owned affiliate of INC Research and will operate as Trident Clinical Research, an INC Research company through its offices in Sydney, Brisbane, Melbourne, Adelaide, Auckland, and Mumbai. Trident’s operation in Mumbai will increase the reach of INC Research’s clinical and data operations located in Gurgaon, India.
“Trident is an important piece in our strategy to build a sustainable CRO business that both satisfies and anticipates the global drug development needs of our customers,” said James Ogle, CEO of INC Research.
Founded in 1997, Trident has strategically grown to become one of Australia’s larges CROs with more than 100 employees across three countries, a full range of clinical research services, and diverse therapeutic experience. Trident has more than 500 clinical studies completed across Phase I to IV, including over 100 Phase I studies.
Based on data from the Economist Intelligence Unit, Australia offers significant cost advantages, has a highly efficient regulatory system according to timeline indicators and is a desirable location to conduct early phase clinical trials, especially when compared to the USA, UK, Germany, Japan and Singapore. Australia achieves very rapid study timelines without the need for IND or CTA. For these reasons, Australia is becoming a prime destination for conducting first-in-man and early phase clinical studies.